Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

A pill from Eli Lilly helped patients improve their blood sugar and shed weight, results that could propel the ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.

Doctors field hundreds of calls about Mounjaro availability Patients now have alternatives to overseas, black market Entry gives Lilly edge over Novo Nordisk in huge market Sign up here.